Globus Medical, Inc. (NYSE:GMED) Expected to Post FY2026 Earnings of $3.77 Per Share

Globus Medical, Inc. (NYSE:GMED) – Zacks Research increased their FY2026 earnings per share (EPS) estimates for Globus Medical in a research report issued on Monday, May 6th. Zacks Research analyst R. Department now anticipates that the medical device company will post earnings of $3.77 per share for the year, up from their previous forecast of $3.76. The consensus estimate for Globus Medical’s current full-year earnings is $2.69 per share.

Globus Medical (NYSE:GMED) last released its earnings results on Tuesday, May 7th. The medical device company reported $0.72 earnings per share for the quarter, topping analysts’ consensus estimates of $0.55 by $0.17. Globus Medical had a return on equity of 8.82% and a net margin of 7.83%. The company had revenue of $606.67 million during the quarter, compared to the consensus estimate of $586.82 million. During the same quarter in the previous year, the company posted $0.53 EPS. Globus Medical’s quarterly revenue was up 119.3% compared to the same quarter last year.

Several other brokerages have also recently weighed in on GMED. Barclays increased their target price on Globus Medical from $83.00 to $85.00 and gave the company an “overweight” rating in a report on Thursday. Stifel Nicolaus upped their price target on shares of Globus Medical from $64.00 to $70.00 and gave the company a “buy” rating in a report on Wednesday. BTIG Research raised their price target on shares of Globus Medical from $60.00 to $63.00 and gave the stock a “buy” rating in a report on Wednesday. Royal Bank of Canada reaffirmed an “outperform” rating and set a $70.00 price objective on shares of Globus Medical in a research note on Thursday, January 11th. Finally, Piper Sandler raised their target price on Globus Medical from $55.00 to $60.00 and gave the stock a “neutral” rating in a research note on Wednesday. Six equities research analysts have rated the stock with a hold rating and six have issued a buy rating to the company’s stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $66.50.

Globus Medical Price Performance

Shares of Globus Medical stock opened at $64.40 on Thursday. The company has a fifty day moving average of $52.71 and a 200-day moving average of $51.35. Globus Medical has a 52-week low of $43.38 and a 52-week high of $65.74. The stock has a market capitalization of $8.72 billion, a price-to-earnings ratio of 55.04, a price-to-earnings-growth ratio of 1.53 and a beta of 1.11. The company has a debt-to-equity ratio of 0.10, a quick ratio of 2.72 and a current ratio of 4.88.

Institutional Trading of Globus Medical

Hedge funds and other institutional investors have recently modified their holdings of the business. Vanguard Group Inc. increased its position in Globus Medical by 49.7% during the 3rd quarter. Vanguard Group Inc. now owns 11,245,502 shares of the medical device company’s stock valued at $558,339,000 after buying an additional 3,732,959 shares in the last quarter. Norges Bank purchased a new stake in Globus Medical during the 4th quarter valued at about $95,537,000. Paradice Investment Management LLC bought a new stake in Globus Medical during the 3rd quarter valued at about $55,053,000. Nuance Investments LLC raised its holdings in Globus Medical by 36.8% in the third quarter. Nuance Investments LLC now owns 3,620,518 shares of the medical device company’s stock worth $179,759,000 after buying an additional 974,693 shares during the last quarter. Finally, Vestal Point Capital LP bought a new position in shares of Globus Medical in the fourth quarter worth approximately $42,632,000. 95.16% of the stock is owned by hedge funds and other institutional investors.

Insiders Place Their Bets

In other news, Director Leslie V. Norwalk sold 10,590 shares of the stock in a transaction that occurred on Friday, March 15th. The stock was sold at an average price of $51.99, for a total value of $550,574.10. Following the completion of the transaction, the director now owns 17,419 shares of the company’s stock, valued at approximately $905,613.81. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. 24.30% of the stock is currently owned by company insiders.

Globus Medical Company Profile

Globus Medical, Inc, a medical device company, develops and commercializes healthcare solutions for patients with musculoskeletal disorders in the United States and internationally. The company offers spine products, such as traditional fusion implants comprising pedicle screw and rod systems, plating systems, intervertebral spacers, and corpectomy devices for treating degenerative and congenital conditions, deformity, tumors, and trauma injuries; treatment options for motion preservation technologies that consist of dynamic stabilization, total disc replacement, and interspinous distraction devices; interventional solutions to treat vertebral compression fractures; and regenerative biologic products comprising of allografts and synthetic alternatives.